JP2008523084A5 - - Google Patents

Download PDF

Info

Publication number
JP2008523084A5
JP2008523084A5 JP2007545629A JP2007545629A JP2008523084A5 JP 2008523084 A5 JP2008523084 A5 JP 2008523084A5 JP 2007545629 A JP2007545629 A JP 2007545629A JP 2007545629 A JP2007545629 A JP 2007545629A JP 2008523084 A5 JP2008523084 A5 JP 2008523084A5
Authority
JP
Japan
Prior art keywords
tlr8
immunostimulatory
combination
oligonucleotide
biological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007545629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008523084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044448 external-priority patent/WO2006063152A2/en
Publication of JP2008523084A publication Critical patent/JP2008523084A/ja
Publication of JP2008523084A5 publication Critical patent/JP2008523084A5/ja
Withdrawn legal-status Critical Current

Links

JP2007545629A 2004-12-08 2005-12-08 免疫賦活用合剤および方法 Withdrawn JP2008523084A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63414604P 2004-12-08 2004-12-08
PCT/US2005/044448 WO2006063152A2 (en) 2004-12-08 2005-12-08 Immunostimulatory combinations and methods

Publications (2)

Publication Number Publication Date
JP2008523084A JP2008523084A (ja) 2008-07-03
JP2008523084A5 true JP2008523084A5 (enExample) 2009-01-29

Family

ID=36578582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545629A Withdrawn JP2008523084A (ja) 2004-12-08 2005-12-08 免疫賦活用合剤および方法

Country Status (4)

Country Link
US (1) US20100113565A1 (enExample)
EP (1) EP1819226A4 (enExample)
JP (1) JP2008523084A (enExample)
WO (1) WO2006063152A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR101494056B1 (ko) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
WO2005048933A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US8709445B2 (en) 2007-07-31 2014-04-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists
CN103977394B (zh) 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
US20120252869A1 (en) * 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
LT2606047T (lt) 2010-08-17 2017-04-10 3M Innovative Properties Company Imuninio atsako modifikatoriaus junginio lipidizuotos kompozicijos, sudėtys ir būdai
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2015095780A1 (en) * 2013-12-20 2015-06-25 The University Of Kansas Toll-like receptor 8 agonists
WO2017038909A1 (en) * 2015-08-28 2017-03-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
US11365413B2 (en) * 2018-08-22 2022-06-21 Board Of Regents, The University Of Texas System Inhibition of poly(A) binding protein and the treatment of pain
CN115916978A (zh) * 2020-05-19 2023-04-04 哈德森医学研究所 寡核苷酸

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
CA2480775C (en) * 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
JP2007513165A (ja) * 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法

Similar Documents

Publication Publication Date Title
JP2008523076A5 (enExample)
ZA200802892B (en) Vaccines and methods to treat canine influenza
BRPI0811473A2 (pt) Compostos hidrossolúveis de magnésio como agentes de limpeza e métodos de utilização dos mesmos.
IL245489A0 (en) New 1-aryl-3-azabicyclo[0.1.3]hexanes, their preparation and their use for the treatment of neuropsychotic disorders
EP1896071A4 (en) METHODS AND COMPOSITIONS WITH ENHANCED THERAPEUTIC EFFECT
BRPI0819533A2 (pt) Microorganismos para melhorar o estado de saúde de indivíduos com desordens relacionadas com a ingestão de glúten
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
IL186616A (en) Spyro-oxa-indoles and their use as drugs
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
CR10075A (es) Bifenilcarboxamidas para combatir microorganismos.
BRPI0719995A2 (pt) Composições e métodos para tratar distúrbios musculares & cardiovasculares
PL1904056T3 (pl) Zastosowanie makrolidu do przywracania czucia rogówkowego
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
BRPI0811218A2 (pt) Agentes de limpeza para pele e mãos com emolientes hidrofílicos
IL192132A0 (en) Long term treatment of hiv-infection with tcm278
NO20051478L (no) Plugg med gripeanordning
ZA200804239B (en) Novel unsaturated fatty hydroxy acid derivatives and the dermocosmetologic use thereof
EP2095826A4 (en) NERVENELONGATION PROMOTER AND ELONGATION INHIBITOR
CL2007003553A1 (es) Uso de epotilonas para tratar enfermedades asociadas con un desequilibrio entre la actividad osteoblastica y osteoclastica.
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
IL185575A0 (en) Benzoxazocines and their therapeutic use
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
IL192715A0 (en) Animal model for hiv induced disease